Every state in the nation, including those led by Democrats, has joined President Trump's most favored nation drug pricing program for Medicaid, a move the administration says will save tens of billions of dollars by forcing pharmaceutical companies to match prices paid overseas.
Trump announced Friday that all 50 states, plus Washington, D.C., and Puerto Rico, will participate in the Medicaid "GENEROUS" payment model, which pegs the price of select prescription drugs to what other wealthy countries pay. The program builds on deals the administration has struck with 26 major pharmaceutical companies since late September 2025, Breitbart reported.
The announcement lands less than two months before the November midterm elections, with cost-of-living pressures still dominating voter concerns. The White House estimated in May that the pharmaceutical deals could save $529 billion over the next decade. The Council of Economic Advisers put Medicaid-specific savings at more than $64 billion over a shorter period.
The universal buy-in is the political headline. Trump's executive order last year committed the United States to paying the lowest price any nation in the world pays for a given medication, a concept known as most favored nation pricing. Skeptics on the left predicted Democratic governors would refuse to participate.
They didn't. CMS Administrator Dr. Mehmet Oz framed the result in blunt terms, as the New York Post reported:
"It is such a good deal that every state realized they need to take it."
Oz also told the president that the program is "rescuing state budgets." For governors facing tight Medicaid budgets, the math apparently outweighed partisan reluctance. The 26 companies that signed on agreed to match drug prices from eight high-income nations, including Canada, Germany, Japan, and the United Kingdom.
Trump himself noted the dynamic during the announcement, saying that "some of the blue states tried not to" participate but "couldn't help it when you're getting your drugs for 70, 80, 90% less."
The savings figures are large. Whether they hold up to scrutiny is a separate question, and one that outside experts have pressed the administration to answer. The specific terms of the deals between the White House and each pharmaceutical company have not been made public, the Associated Press reported.
Kathy Hempstead, a senior policy advisor at the Robert Wood Johnson Foundation, told the AP that the secrecy creates a real barrier, both for Congress and for anyone trying to verify the administration's cost projections.
"He is saying Congress should codify all of his MFN arrangements. But it's kind of unreasonable because it's not clear what Congress would actually do. No one knows what is in these deals."
Hempstead also raised a durability question: if the deals are executive agreements rather than statutory changes, the price cuts could vanish when the current administration leaves office. That concern gives the White House an incentive to push Congress toward legislation, but Congress can't draft a law around terms it hasn't seen.
JD Hayworth, a former Republican congressman who now speaks for the Pharmaceutical Reform Alliance, acknowledged the gap between what has been achieved and what remains undone. In a statement, he called the announcement "meaningful progress, but that progress remains incomplete," noting that millions of Americans who are not enrolled in government healthcare still want lower drug prices.
One concrete step came earlier when Trump and Pfizer CEO Albert Bourla announced a direct agreement in the Oval Office to lower medication costs for Medicaid patients. New pricing under that deal is expected to take effect as early as the beginning of next year, the Washington Examiner reported.
The Pfizer agreement illustrates the administration's company-by-company approach. Rather than passing a single statute through Congress, the White House has negotiated individual deals with 26 drugmakers, a strategy that has produced results but also explains why so little detail is publicly available. Each deal is its own negotiation, with its own terms.
For Medicaid patients, the immediate practical effect may be modest in one sense: they already pay only a few dollars in co-payments to fill prescriptions. The larger impact falls on state budgets, which bear a significant share of Medicaid drug costs. Lower wholesale prices mean states spend less, freeing money for other services or reducing the fiscal pressure that has driven some states to cut Medicaid eligibility in recent years.
The administration also unveiled a "TrumpRx" platform offering prescription drug discounts for uninsured Americans, ABC News reported. That initiative extends the pricing effort beyond government insurance programs to reach people who currently pay full retail prices at the pharmacy counter.
Details on TrumpRx remain thin. But the political logic is straightforward: Medicaid covers low-income Americans, Medicare covers seniors, and the uninsured fall through both cracks. A discount card that delivers even partial savings to that population fills a visible gap, and does so before voters head to the polls in November.
Several issues remain unresolved. Which specific drugs are covered under the GENEROUS model has not been publicly detailed. The methodology behind the $529 billion savings estimate has not been released. And the question of whether these deals survive a future administration is unanswered, a point both Hempstead and Hayworth raised from different angles.
Trump has called on Congress to codify the MFN arrangements into law. That would make the price reductions permanent and remove the legal uncertainty that hangs over executive agreements. But legislators from both parties will reasonably want to see the terms before they vote to lock them in, and so far, the administration has not provided that transparency.
The tension is real: the program appears to be delivering lower prices, every state has voluntarily signed on, and the pharmaceutical industry is cooperating. Those are facts. But the full scope of what taxpayers are getting, and what the drug companies are giving up, remains hidden behind closed-door negotiations.
Americans deserve to know the terms of the deals being struck in their name. If the savings are as large as the White House claims, sunlight will only strengthen the case, and if they aren't, voters deserve to know that before November, not after.